RxDoctor Payments Data

Krupa Rajur, MD

Nephrology · Nashua, NHNPI 1841365913

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $296 of the $438 with a category attached, or 67.6%. 11 manufacturers reported payments, led by Amgen at 27.8% of the total. 2025 is the largest year on record at $149, 2.7 times the $55 reported in 2019.

$438in general payments, 2019–2025

Across 15 payments — averaging $29.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$122
  • Calliditas Therapeutics US Inc.$50
  • Vantive US Healthcare LLC$44
  • Akebia Therapeutics Inc$39
  • AstraZeneca$33
  • Ardelyx, Inc.$32
  • plus $119 from 5 others

What the payments were for

  • Food & beverage$29668%
  • Education$14232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$438 in reported general payments places this provider in the 75th percentile of 33 nephrology providers in New Hampshire.

See all nephrology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$166,357
Medicare patients
285
Services billed
873

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate26$10,592
ProsolParenteral Amino Acid 20% No.115$2,306
Furosemide40$401
Torsemide27$322
Allopurinol40$315
Calcitriol26$301
Nifedipine ErNifedipine12$239
Chlorthalidone17$176
Amlodipine Besylate16$145
Spironolactone21$142
Valsartan13$142
Lisinopril18$127
Clonidine Hcl12$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$33$10,59226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 33 nephrology providers in New Hampshire.

Other nephrology in Nashua

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →